TD Cowen lowered the firm’s price target on DarioHealth to $5 from $13 and keeps an Outperform rating on the shares. The firm said going into 2024 the focus is on the trajectory of B2B2C ramping existing and new clients as well as leveraging strategic partners to win new business.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DRIO:
- DarioHealth price target lowered to $2.50 from $4.10 at Alliance Global Partners
- DarioHealth reports Q3 EPS (49c), consensus (46c)
- DarioHealth Reports Third Quarter 2023 Financial and Operating Results
- DarioHealth launches new smart blood sugar meter for Apple iPhone 15
- DarioHealth to host investor day
